^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    SureSeq™ Myeloid MRD Panel

    Company:
    Sysmex Corp
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    3ms
    OGT expands NGS operations to state-of-the-art facility in Oxford Technology Park (Sysmex Press Release)
    "OGT...announces the opening of state-of-the-art facilities within the Oxford Technology Park. The move represents a multi-million-pound investment, fuelled by consistent company growth and growing customer demand. Equipped with cutting-edge technology, the facilities will drive development of OGT’s trusted SureSeq™ next generation sequencing (NGS) product portfolio, as well as deliver expert-led training and enhanced opportunities for collaboration."
    Clinical
    |
    SureSeq™ CLL + CNV Panel • SureSeq™ Germline Breast Cancer + CNV Panel • SureSeq™ Myeloid MRD Panel • SureSeq™ Myeloid Plus Panel • SureSeq™ Pan-Myeloid Panel
    6ms
    OGT to premiere SureSeq Myeloid MRD panel for AML disease monitoring at AMP (Sysmex Press Release)
    "OGT, A Sysmex Group Company, will showcase its soon to be launched SureSeq™ Myeloid MRD Panel at booth #1423 at the Association for Molecular Pathology (AMP) 2023 Annual Meeting & Expo, 14-18th November in Salt Lake City. The Next-generation sequencing (NGS) panel represents a substantial improvement on conventional flow cytometry and qPCR methods of detecting measurable residual disease (MRD) in acute myeloid leukaemia (AML) samples—providing outstanding sensitivity and coverage uniformity in one rapid and cost-effective assay."
    Clinical
    |
    SureSeq™ Myeloid MRD Panel